New cancer drug enters human testing: could help control advanced tumors
NCT ID NCT06421935
Summary
This early-stage study is testing a new cancer drug called M9466, both alone and in combination with other therapies, in 141 people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check if the drug is safe and how the body processes it, while also looking for early signs that it might help control cancer growth. This is the first time M9466 is being tested in humans, so researchers are carefully monitoring side effects and how the drug behaves in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
Cancer Institute Hospital of JFCR
Kōtoku, Japan
-
Cancer Research SA
Adelaide, Australia
-
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica
Madrid, Spain
-
GenesisCare North Shore (Oncology)
St Leonards, Australia
-
Harasanshin Hospital
Fukuoka, Japan
-
Hospital HM Nou Delfos - START Barcelona
Barcelona, Spain
-
Hospital Universitari Vall d'Hebron - Oncology Dept.
Barcelona, Spain
-
Hospital Universitario 12 de Octubre - Servicio de Oncologia
Madrid, Spain
-
Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I
Madrid, Spain
-
ICO l'Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia
Barcelona, Spain
-
NEXT Madrid - Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Spain
-
NEXT Oncology - PARENT
New York, New York, 10065, United States
-
NHO Kumamoto Medical Center - Dept of Urology
Kumamoto, Japan
-
National Cancer Center Hospital East - Dept of Experimental Therapeutics
Kashiwa-shi, Japan
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System - Division of Infectious Diseases
Seoul, South Korea
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.